Patients fighting life-threatening illnesses who have run out of conventional options will get a chance to try some of the most cutting-edge treatments available, through a national effort that just received nearly $4.8 million in funding from the federal government.
Based at the University of Michigan, in partnership with Duke University, the University of Texas Southwestern Medical Center and the University of Rochester, the effort will build a national framework to help more patients gain access to experimental drugs, devices and biologics. It is funded by the National Center for Advancing Translational Sciences, part of the National Institutes of Health.
Tanner Caverly was recently interviewed for U.S. News & World Report on the risks and benefits of lung cancer screening. According to Dr. Caverly, it important to tailor the conversation about screening because the benefit-versus-risk calculation differs for each patient.